Literature DB >> 19648788

Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the Children's Cancer Group Protocol 1953: a report from the Children's Oncology Group.

Wanda Salzer1, Patricia Dinndorf, Zoann Dreyer, Joanne Hilden, Gregory H Reaman.   

Abstract

Infants with acute lymphoblastic leukemia have a poor prognosis. The Children's Cancer Group (CCG) 1953 protocol tested the hypothesis that intensification of therapy would improve outcome for these patients. This intensified therapy resulted in better disease control, but resulted in greater toxicity. In this paper, we report the infectious complications associated with this intensified therapy. We retrospectively analyzed the infectious complications reported on the case report forms of all 115 patients enrolled on CCG 1953. Overall 495 infectious complications were identified in 115 patients. Bacterial infections occurred most frequently (74%), followed by viral (13%), fungal (11%), and protozoan (1%). Infection related mortality disproportionately occurred with viral (31%) and fungal (19%) infections. Twenty-three percent (n=26) of patients died of infectious complications, with the majority occurring during induction/intensification. Lower respiratory infections contributed to death in 12 patients and were most commonly viral (n=6) and fungal (n=3). Intensification of therapy resulted in increased infectious complications and deaths compared with previous studies. Future studies will need to focus on: (1) decreasing intensification during the first month of therapy, (2) developing targeted therapies, and (3) improving measures designed to prevent, quickly diagnose, and appropriately treat infections.

Entities:  

Mesh:

Year:  2009        PMID: 19648788     DOI: 10.1097/MPH.0b013e3181a6dec0

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

1.  Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.

Authors:  Wanda L Salzer; Tamekia L Jones; Meenakshi Devidas; ZoAnn E Dreyer; Lia Gore; Naomi J Winick; Lillian Sung; Elizabeth Raetz; Mignon L Loh; Cindy Y Wang; Paola De Lorenzo; Maria Grazia Valsecchi; Rob Pieters; William L Carroll; Stephen P Hunger; Joanne M Hilden; Patrick Brown
Journal:  Pediatr Blood Cancer       Date:  2014-11-18       Impact factor: 3.167

2.  Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407.

Authors:  Wanda L Salzer; Tamekia L Jones; Meenakshi Devidas; Joanne M Hilden; Naomi Winick; Stephen Hunger; William L Carroll; Bruce Camitta; ZoAnn E Dreyer
Journal:  Pediatr Blood Cancer       Date:  2012-04-05       Impact factor: 3.167

Review 3.  Acute Leukemia in Infants.

Authors:  Azada Ibrahimova; Lauren Pommert; Erin H Breese
Journal:  Curr Oncol Rep       Date:  2021-02-12       Impact factor: 5.075

4.  Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia.

Authors:  Azada Ibrahimova; Lena E Winestone; Tamara P Miller; Kyle Kettler; Alix E Seif; Yuan-Shung Huang; Caitlin W Elgarten; Regina M Myers; Brian T Fisher; Richard Aplenc; Kelly D Getz
Journal:  Pediatr Blood Cancer       Date:  2021-03-11       Impact factor: 3.167

5.  Fungal colonization of the respiratory tract in allogeneic and autologous hematopoietic stem cell transplant recipients: a study of 573 transplanted patients.

Authors:  Jarosław Markowski; Grzegorz Helbig; Agnieszka Widziszowska; Wirginia Likus; Sławomira Kyrcz-Krzemień; Urszula Jarosz; Włodzimierz Dziubdziela; Mirosław Markiewicz
Journal:  Med Sci Monit       Date:  2015-04-24

6.  The evolution of clinical trials for infant acute lymphoblastic leukemia.

Authors:  R S Kotecha; N G Gottardo; U R Kees; C H Cole
Journal:  Blood Cancer J       Date:  2014-04-11       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.